Recombinant Human Vasopressin V2 receptor (AVPR2)

What is the basic structure and function of the human AVPR2 receptor?

AVPR2 is the vasopressin receptor type 2, belonging to the seven-transmembrane-domain G protein-coupled receptor (GPCR) superfamily. It couples to Gs protein, thus stimulating adenylate cyclase when activated. The receptor is primarily expressed in kidney tubules, predominantly in the distal convoluted tubule and collecting ducts, where it responds to the pituitary hormone arginine vasopressin (AVP) to stimulate mechanisms that concentrate urine and maintain water homeostasis in the organism . The structural organization of AVPR2 follows the canonical GPCR architecture with seven transmembrane domains connected by intracellular and extracellular loops, with distinct regions for ligand binding and G-protein coupling.

How does arginine vasopressin (AVP) activate the AVPR2 receptor?

AVP activation of AVPR2 involves specific conformational changes within the receptor structure. Upon AVP binding, V2R undergoes notable conformational alterations including outward displacement of the cytoplasmic end of transmembrane helix 6 (TM6), which is considered a hallmark of GPCR activation . This activation follows a common pathway that directly links the ligand-binding pocket to G-protein coupling regions. The process involves turning of the rotamer "toggle switch" W284^6.48, which translates into rotation and outward movement of TM6 . Additionally, V2R demonstrates receptor-specific activation features compared to other class A GPCRs, including the formation of hydrogen bonds between Y280^6.44 and S127^3.40, as well as between Y280^6.44 and the backbone CO group of V213^5.46, which likely stabilize the active conformation of the receptor .

What are the optimal methods for recombinant expression and purification of AVPR2?

For effective expression and purification of AVPR2, researchers have successfully employed a construct containing specific elements to facilitate expression and purification while maintaining native function. A validated approach involves incorporating a hemagglutinin signal peptide (MKTIIALSYIFCLVFA), Flag-tags, Twin-Strep-tag (WSHPQFEKGGGSGGGSGGGSWSHPQFEK), and a human rhinovirus 3C (HRV3C) protease cleavage site into the N-terminus of the AVPR2 construct .

Additionally, substituting N22 with a glutamine residue prevents N-glycosylation. This construct should be validated in HEK cells to confirm that it retains wild-type pharmacological and functional properties before production in Sf9 insect cells . Validation should include measurement of the dissociation constant (Kd) of fluorescently labeled antagonists, AVP binding assays, cytosolic cAMP accumulation tests, and β-arrestin recruitment assays to ensure full functionality of the recombinant receptor .

How can researchers effectively model the AVPR2 structure for in silico studies?

In silico modeling of AVPR2 presents challenges due to limited template availability. When BLAST similarity searches and multiple alignments fail to identify suitable templates (sequence similarity less than 40%), alternative approaches must be employed . For AVPR2 modeling, researchers can:

• Use the NCBI reference sequence of vasopressin V2 receptor isoform 1 (Homo sapiens) NP-000045.1 as a starting point .

• Apply template specification methods in Swiss-model even when sequence identity is low .

• Estimate model quality using distance constraints methods .

• Perform structural analyses, secondary structural observations, and mapping of binding regions and GPCR-family conserved residues using visualization software like PyMOL .

• For predicting effects of mutations, generate mutant structures using wild-type AVPR2 structures as templates, followed by local network analysis of intramolecular interactions .

This methodological approach enables the prediction of structural changes caused by mutations and helps in understanding the molecular basis of receptor function and dysfunction.

What does the cryo-EM structure of AVPR2 reveal about its activation mechanism?

The cryo-electron microscopy (cryo-EM) structure of AVPR2 has provided crucial insights into its activation mechanism. Near-atomic resolution cryo-EM structures of the full-length, Gs-coupled human V2R bound to AVP have been determined . This structure reveals that the cytoplasmic end of TM6 in Gs-coupled V2R undergoes a notable outward displacement during activation, consistent with the common activation mechanism of class A GPCRs .

The structure shows a direct link between the ligand-binding pocket and G-protein coupling regions, involving the rotation of the "toggle switch" W284^6.48, which translates into rotation and outward movement of TM6 . Several distinct features in the active V2R conformation suggest receptor-specific activation mechanisms. For example, the unique physicochemical environment in V2R facilitates hydrogen bond formation between Y280^6.44 and S127^3.40, as well as between Y280^6.44 and the backbone CO group of V213^5.46, which likely stabilize the active receptor conformation .

What is known about the AVPR2-β-arrestin1 complex structure?

The cryo-electron microscopy structure of the wild-type arginine-vasopressin V2 receptor (V2R) in complex with β-arrestin1 provides crucial insights into GPCR-arrestin interactions . This active complex structure elucidates the molecular mechanism of signal transduction and receptor desensitization.

The structure demonstrates how β-arrestin1 binds to the phosphorylated C-terminal tail of activated AVPR2, leading to receptor internalization and signal termination. While specific details of the interface aren't fully provided in the available search results, the successful purification and structural determination of this complex represents a significant advance in understanding GPCR regulation . This structure is particularly important for understanding the biased signaling properties of AVPR2 and has implications for drug design targeting this pathway.

What are the molecular mechanisms by which AVPR2 mutations cause Nephrogenic Diabetes Insipidus?

Mutations in the AVPR2 gene are a primary cause of X-linked Nephrogenic Diabetes Insipidus (NDI), a rare disorder characterized by renal unresponsiveness to vasopressin, leading to excretion of large volumes of diluted urine . Multiple molecular mechanisms have been identified:

• Impaired transcription: Some mutations affect the proper transcription of the AVPR2 gene.

• Endoplasmic reticulum retention: Many mutant receptors are misfolded and consequently retained in the endoplasmic reticulum, preventing their trafficking to the cell surface.

• Defective ligand binding: Some mutants reach the cell surface but cannot properly bind vasopressin.

• Impaired signal transduction: Other mutants fail to trigger intracellular cAMP signaling despite normal ligand binding .

How can functional characterization of novel AVPR2 variants be performed?

Functional characterization of novel AVPR2 variants involves a multi-faceted approach:

• Genetic analysis: PCR amplification and direct DNA sequencing of the AVPR2 gene to identify variants, followed by restriction enzyme analysis for confirmation .

• In silico prediction: Use of prediction tools like PolyPhen-2, SIFT, PROVEAN, and MutationTaster to assess potential pathogenicity .

• Population database analysis: Checking variant presence in databases like gnomAD and 1000 Genomes Project .

• Structural modeling: Using Swiss-model to model the mutant receptor structure and predict effects on protein folding and function .

• Functional assays:

  • Measurement of ligand binding affinity

  • cAMP accumulation assays to assess G-protein coupling

  • β-arrestin recruitment assays

  • Cell surface expression analysis using immunological techniques

  • Coimmunoprecipitation studies to assess protein-protein interactions

• Classification of variants according to ACMG criteria to determine pathogenicity (e.g., PM1, PM2, PP2, PP3 for "Likely Pathogenic") .

This comprehensive approach enables researchers to determine whether a novel variant is disease-causing and provides insights into the molecular mechanisms of receptor dysfunction.

What rescue strategies exist for functionally inactive mutant AVPR2 receptors?

Several innovative approaches have been developed to rescue functionally inactive mutant AVPR2 receptors:

• Receptor fragment co-expression: Studies have demonstrated that functionally inactive mutant V2 vasopressin receptors can be rescued by co-expression of a carboxy-terminal V2 receptor fragment (V2-tail) spanning the region where various mutations occur . This approach works through a direct and highly specific interaction between the mutant V2 vasopressin receptor proteins and the V2-tail polypeptide, as demonstrated through coimmunoprecipitation strategies and sandwich ELISA systems .

• Adenovirus-mediated gene transfer: This has proven to be a highly efficient method for achieving expression of the V2-tail fragment (as well as the wild-type V2 receptor) in various cell types. In Chinese hamster ovary (CHO) cell lines stably expressing low levels of functionally inactive mutant V2 vasopressin receptors, adenovirus infection carrying the V2-tail gene fragment enabled vasopressin to stimulate cAMP formation with high potency and efficacy . Similar success was observed in Madin-Darby canine kidney tubular cells .

• Pharmacological chaperones: Although not directly mentioned in the search results, this is another established approach where small molecules bind to misfolded receptors in the endoplasmic reticulum, stabilizing them and facilitating their proper folding and trafficking to the cell surface.

These rescue strategies provide potential therapeutic avenues for treating diseases caused by AVPR2 mutations, particularly Nephrogenic Diabetes Insipidus.

How might adenovirus-mediated expression of receptor fragments be developed as a treatment strategy?

Adenovirus-mediated expression of receptor fragments represents a promising therapeutic approach for treating AVPR2-related disorders, particularly Nephrogenic Diabetes Insipidus caused by mutant receptors. The development pathway includes:

• Construct design: The V2-tail gene fragment must be optimized for expression and incorporated into an appropriate adenoviral vector .

• Validation in cell culture: As demonstrated in CHO cell lines stably expressing mutant V2 receptors, adenoviral delivery of the V2-tail fragment restored vasopressin's ability to stimulate cAMP formation with high potency and efficacy .

• Testing in relevant kidney cell models: Successful expression has been achieved in Madin-Darby canine kidney tubular cells, an important model for renal physiology .

• Mechanism elucidation: Understanding that a direct and specific interaction between the mutant receptor and the V2-tail polypeptide underlies functional rescue is crucial for optimizing the approach .

• Scaling for therapeutic application: Determining optimal viral titers, expression levels, duration of expression, and potential immune responses.

• Targeted delivery: Development of kidney-specific targeting strategies to minimize off-target effects.

This approach has broader implications beyond AVPR2-related disorders, as it suggests that adenovirus-mediated expression of receptor fragments may lead to novel strategies for treating a variety of human diseases caused by mutationally inactivated G protein-coupled receptors .

How can in silico methods be used to study AVPR2 hormone binding site interactions?

In silico methods provide valuable tools for studying AVPR2-hormone binding interactions:

• Docking studies: Molecular docking of AVP to the V2 receptor model helps identify important amino acid residues involved in AVP binding. This approach allows prediction of binding modes and interaction energies between the hormone and receptor .

• Homology modeling: When direct structural data is unavailable, models can be constructed based on related receptors, though AVPR2 presents challenges due to limited template availability .

• Multiple sequence alignment: Tools like T-Coffee (Tree-Based Consistency Objective Function for Alignment Evaluation) software can be used to analyze sequence conservation across vasopressin receptors, identifying potential functional motifs .

• Structure similarity analysis: When sequence similarity is insufficient (less than 40%), structure similarity methods can be attempted, though the RMSD values should be less than 2 for reliable models .

• Network analysis of intra-molecular interactions: This approach helps predict how mutations affect receptor structure and function by analyzing changes in the local interaction network .

These computational approaches complement experimental studies and can guide the design of experiments, predict the effects of mutations, and assist in drug discovery efforts targeting AVPR2.

What are the latest methods for studying AVPR2 activation and signaling pathways?

Contemporary approaches to studying AVPR2 activation and signaling pathways include:

• Cryo-electron microscopy: Near-atomic resolution cryo-EM structures of the full-length, Gs-coupled human V2R bound to AVP provide detailed insights into receptor activation mechanisms . This technique has revealed critical conformational changes like the outward displacement of TM6 and rotation of the "toggle switch" W284^6.48 .

• Site-directed mutagenesis: Experimental validation of key residues identified in structural studies. For example, disease-associated mutations S127^3.40F and Y280^6.44C have been shown to deactivate V2R, confirming their role in receptor activation . Similarly, the alanine mutation of F284^6.44 abolished binding and activation of the related oxytocin receptor .

• Comparative studies with related receptors: Replacing F284^6.44 in the oxytocin receptor with the V2R-equivalent tyrosine slightly decreased activation by AVP but converted AVP from a partial to a full agonist, providing insights into receptor-specific activation mechanisms .

• CAMP accumulation assays: For assessing Gs-coupling and receptor activation .

• β-arrestin recruitment assays: For studying receptor desensitization pathways .

• Fluorescent ligand binding assays: For determining binding affinities and kinetics .

These methods collectively provide a comprehensive toolkit for dissecting the molecular mechanisms of AVPR2 activation and signaling, essential for understanding receptor function in health and disease.

What is the significance of de novo AVPR2 variants in sporadic cases of Nephrogenic Diabetes Insipidus?

De novo AVPR2 variants play a significant role in sporadic cases of Congenital Nephrogenic Diabetes Insipidus (CNDI). While CNDI typically follows an X-linked recessive inheritance pattern with a known family history, sporadic cases without family history can occur due to de novo mutations . The significance of identifying these de novo variants includes:

• Diagnostic precision: Identification of de novo disease-causing variants facilitates precise diagnosis of CNDI in patients without family history .

• Early intervention: Early diagnosis and treatment of CNDI are essential due to the risk of intellectual disability caused by repeated episodes of dehydration and rapid rehydration .

• Family genetic counseling: Detection of de novo variants provides critical information for future genetic counseling in the family .

• Understanding disease mechanisms: Novel variants contribute to our understanding of structure-function relationships in AVPR2.

For example, an 80-bp duplication in exon 2 (c.800_879dup) leading to a frameshift and premature stop codon (p.Ala294Profs*4) was identified as a de novo variant in a Swedish male diagnosed with CNDI at 6 months of age during an episode of gastroenteritis . This variant was absent in unaffected family members and healthy controls, confirming its de novo nature and pathogenicity .

What genetic testing strategies are recommended for diagnosing AVPR2-related disorders?

Comprehensive genetic testing strategies for diagnosing AVPR2-related disorders include:

• PCR amplification and direct DNA sequencing: Analysis of the coding regions of AVPR2 to identify potential variants . This approach successfully identified an 80-bp duplication in exon 2 in a patient with CNDI .

• Restriction enzyme analysis: Used to confirm variants and test for their presence in family members. For example, MwoI restriction enzyme analysis confirmed the presence of a variant in a patient and his father and its absence in the mother .

• Variant classification: Using multiple in silico prediction tools (PolyPhen-2, SIFT, PROVEAN, and MutationTaster) to assess potential pathogenicity, along with checking population databases (gnomAD, 1000 Genomes Project) for variant frequency .

• ACMG criteria application: Applying American College of Medical Genetics criteria to classify variants (e.g., "Likely Pathogenic" based on criteria PM1, PM2, PP2, PP3) .

• Functional validation: When possible, functional studies to assess the impact of the variant on receptor expression, trafficking, and signaling .

• Prenatal testing: For at-risk pregnancies in families with known disease-causing variants .

These strategies are particularly important for early diagnosis in sporadic cases, which can occur due to de novo variants in AVPR2 or through several generations of female transmission of the disease-causing variant .